BriMindInvest Logo

NTLA (NTLA) Stock Analysis 2026

BriMind AI Score

Proprietary
25
Weak
Price CAGR
-4.9%
1Y Return
-7.0%
Analyst Upside
+142.9%
Rev Growth
-9.5%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

Compare NTLA with Peers

NTLA vs CRSPIntellia Therapeutics vs CRISPR Therapeutics — In-Vivo
EDIT vs NTLAEditas Medicine vs Intellia Therapeutics — Two Gene Edi
BEAM vs NTLABeam Therapeutics vs Intellia — Base Editing vs In Vivo

Unlock the Full NTLA Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
← Back to Home · Browse All Stock Analysis

We use cookies to keep you signed in and to understand how people use our site (Google Analytics). You can accept all cookies or limit them to what's strictly necessary. Privacy policy